SIRO ClinPharm and Advanced Clinical Trial Solutions Ink Strategic Alliance
News Apr 20, 2009
SIRO ClinPharm (SIRO) has announced the signing of a strategic alliance with Advanced Clinical Trial Solutions LLC (ACT Solutions), Flemington, NJ, USA, a service provider in oncology drug development with a business concentration in North America.
This alliance will enable SIRO to expand its oncology clinical development and patient recruitment expertise to North America. ACT Solutions and its clients will benefit by gaining access to SIRO's clinical study management, patient recruitment, data management, biostatistics and medical writing capabilities in India and European countries.
"We are delighted to add ACT Solution's North American expertise in our service offering to our customers, said Dr Chetan Tamhankar, COO of SIRO ClinPharm group. "This alliance is the first step for SIRO in creating delivery capabilities in North America."
"We are excited about aligning our strengths in oncology with SIRO's international delivery capabilities," said Patricia Devitt Risse, Pharm. D, President of ACT Solutions LLC. "This step addresses the changing dynamics of the clinical research sector. We remain committed to providing a level of expertise and service that built our reputation and loyal client base to this point and this alliance expands our ability to deliver capabilities in Europe and India," she explained.
An investigational drug for the treatment of sickle cell disease shows early promise in Phase 2a clinical trial. The orally administered drug, given to adult patients with sickle cell disease, is demonstrating tolerability and the ability to impact both red and white blood cell biomarkers of the disease.READ MORE
Researchers report that an experimental drug called vosoritide, allowed the average annual growth rate to increase in a study of 35 children and teenagers with a form of dwarfism. The average boost in height per year was ~6 centimeters (2.4 inches) which is close to growth rates among children of average stature.READ MORE